Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks

benzinga.com/news/health-care/25/10/48184263/tvardi-therapeutics-lung-disease-candidate-fails-to-show-any-clinical-benefit-stock-sinks

Tvardi Therapeutics Inc. (NASDAQ:TVRD) stock is falling on Monday with a session volume of 5.56 million versus the average volume of 42.08 thousand, as per data from Benzinga Pro.
Tvardi Therapeutics provided an update on preliminary data from the Phase 2 REVERT trial of TTI-101 alone or…

This story appeared on benzinga.com, 2025-10-13 18:23:45.
The Entire Business World on a Single Page. Free to Use →